

Dialogues at Pharmamed 2026 lay out roadmap for India's pharma future

28 March 2026 | News

India outlines future of pharma at PharmaMed 2026, with emphasis on flexibility, regulation, and healthcare



The 9th edition of PharmaMed 2026 was organised by PHD Chamber of Commerce and Industry (PHDCCI) in collaboration with Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India in New Delhi on 27 March.

Focused on the theme "Healthcare Equity: Reaching Every Citizen of Viksit Bharat", the inaugural session was attended by senior policy makers, global regulators, industry leaders and experts, setting the stage for a meaningful dialogue on strengthening the country's pharmaceutical sector.

The inaugural session focused on strengthening supply chain resilience, promoting self-reliance in APIs and Key Starting Materials (KSMs). The focus was on key issues including promotion and furthering public-private partnerships.

The session on 'Redefining India's Pharmaceutical Leadership – From Quantity to Value' was attended by representatives from CDSCO, PharmaExil, Cipla and NIPER. The main objective of this session was to propel India's pharmaceutical sector towards high-value innovation. The discussions focused on strengthening research in the field of biologics, advanced therapeutics, and biosimilars.

In the session on 'Strengthening Pharmaceutical Quality – Regulatory Harmonization and Global Compliance', the delegates emphasized on improving quality standards across the supply chain through robust regulatory frameworks and compliance.

Central Drugs Standard Control Organization (CDSCO), Pharmexcil, Cipla, AstraZeneca, Indian Pharmaceutical Producers'

Organization, Serum Institute of India, Biotechnology Industry Research Assistance Council (BIRAC), National Institute of Pharmaceutical Education and Research (NIPER) Mohali, United States Food and Drug Administration (USFDA), Tenet Health Edutech Pvt Ltd, NuLifeCare, Daund Biological, EVERSANA, Jamia Hamdard, Mankind Pharma, Apollo Pharmacy, Tata 1mg, and key organisations and industry stakeholders such as the Association of Healthcare Providers India actively participated in these sessions, contributing their diverse expertise and valuable insights through the sessions.